Markus H.
- Country
- Germany
- Department
- Klinik für Strahlentherapie und Radioonkologie
Research Overview
- Phase II Study of Rilvegostomig Immunotherapy With or Without Combination Chemotherapy in Unresectable Stage III NSCLC Receiving Concurrent Chemoradiotherapy
- Evaluation of Durvalumab in Combination with Cisplatin, Carboplatin, and Etoposide with Radiotherapy in Extensive-Stage Small Cell Lung Cancer
- Efficacy of Pembrolizumab and Lenvatinib Maintenance Therapy Post-Chemoradiation in Locally Advanced PD-L1 Positive Head and Neck Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 14 of 37 partner sites.
Specializations
Head and Neck Cancer Research
The investigator specializes in treating locally advanced head and neck squamous cell carcinoma, with particular focus on combining immunotherapy and targeted therapies following chemoradiation treatments.
- Post-chemoradiation maintenance therapy
- Immunotherapy combinations
- PD-L1 positive HNSCC management
Investigation of novel therapeutic approaches for improving survival outcomes in advanced head and neck cancer patients.
Non-Small Cell Lung Cancer
Expertise in treating locally advanced unresectable NSCLC, implementing innovative FDG-PET-based treatment approaches combined with immunotherapy.
- Accelerated chemoradiotherapy protocols
- PET-guided precision therapy
- Immunotherapy integration
Development of personalized treatment strategies for stage III NSCLC patients with specific biomarker profiles.
Small Cell Lung Cancer
Focus on treating extensive stage SCLC through the integration of multi-modal therapy approaches, combining radiotherapy with immunotherapy treatments.
- Combined radiochemotherapy
- Stereotactic radiotherapy
- Immunotherapy maintenance
Investigation of novel treatment combinations to improve progression-free survival in extensive stage disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.